In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $58.96, denoting a +1.85% move from the preceding trading day.
BMY's Breyanzi tops $1B run rate in 2025, expanding across five cancers with new FDA nod, strengthening its CAR T leadership despite rising competition.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –
Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and off
Carnegie Investment Counsel reduced its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 35.5% during the fourth quarter, according to its most recent 13F filing with the Securities a
Values aren't always easy to find in the pharma sector. Bristol Myers Squibb has stable revenue, plus a strong dividend payout.
BMY stock jumps 10% in a month as growth drugs power revenues, but generic erosion and 2026 sales outlook keep investors cautious.
CVS Health and Bristol Myers Squibb are built to handle the toughest recessions. Both companies have maintained or increased their dividends through downturns over the past two decades.
BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.
Oxford, UK and San Jose, California , 9 April 2026 – Oxford BioTherapeutics (“OBT”), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Ant
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $59.2, indicating a +2.65% shift from the previous trading day.
Leo Wealth LLC increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 36.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Savvy Advisors Inc. raised its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 20.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 57,17
Perpetual Ltd raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 121.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Com
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE